Show simple item record

dc.contributor.authorGrindstad, Thea K.W.
dc.contributor.authorRichardsen, Elin
dc.contributor.authorAndersen, Sigve
dc.contributor.authorSkjefstad, Kaja Konstanse
dc.contributor.authorRakaee, Mehrdad
dc.contributor.authorDønnem, Tom
dc.contributor.authorNess, Nora
dc.contributor.authorNordby, Yngve
dc.contributor.authorBremnes, Roy M.
dc.contributor.authorAl-Saad, Samer
dc.contributor.authorBusund, Lill-Tove
dc.date.accessioned2019-03-20T11:53:08Z
dc.date.available2019-03-20T11:53:08Z
dc.date.issued2018-07-27
dc.description.abstractThe role of steroid hormones in carcinogenesis of the prostate is to some extent unraveled thorough the effect of androgen deprivation therapy on prostate cancer (PCa) progression. Other members of the steroid hormone family, such as progesterone, are also implicated in PCa, but progesterone’s role remains undefined. This study aimed to examine the distribution of progesterone receptor isoforms (PGRA, PGRB) in PCa tissue and their association with clinical endpoints. This was conducted retrospectively by collecting radical prostatectomy specimens from 535 patients. Tissue was analyzed using tissue microarray, where representative tumor areas were carefully selected. Protein expression was evaluated through immunohistochemistry, in stromal and epithelial tissue. Associations between receptor expression and clinical data were considered using statistical survival analyses. Herein, we discovered a solely stromal PGRA- and a stromal and epithelial PGRB expression. Further, a high PGRB expression in tumor tissue was associated with an unfavorable prognosis in both univariate and multivariate analyses: Biochemical failure (HR: 2.0, 95% CI: 1.45–2.76, p < 0.001) and clinical failure (HR: 2.5, 95% CI: 1.29–4.85, p = 0.006). These findings are in agreement with our previous investigation on pan-PGR, indicating that the observed negative effect of PGR is represented by PGRB.en_US
dc.description.sponsorshipNorwegian Cancer Society UiT Arctic University of Norway The publication fund of UiT The Arctic University of Norwayen_US
dc.descriptionSource at <a href=https://doi.org/10.1038/s41598-018-29520-5> https://doi.org/10.1038/s41598-018-29520-5</a>.en_US
dc.identifier.citationGrindstad, T., Richardsen, E.R., Andersen, S., Skjefstad, K., Rakaee, M., Dønnem, T., ... Busund, L.-T. (2018). Progesterone receptors in prostate cancer: Progesterone receptor B is the isoform associated with disease progression. <i>Scientific Reports, 8</i>, 11358. https://doi.org/10.1038/s41598-018-29520-5en_US
dc.identifier.cristinIDFRIDAID 1605039
dc.identifier.doi10.1038/s41598-018-29520-5
dc.identifier.issn2045-2322
dc.identifier.urihttps://hdl.handle.net/10037/15033
dc.language.isoengen_US
dc.publisherPublic Library of Scienceen_US
dc.relation.journalScientific Reports
dc.rights.accessRightsopenAccessen_US
dc.subjectVDP::Medical disciplines: 700::Basic medical, dental and veterinary science disciplines: 710en_US
dc.subjectVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762en_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en_US
dc.titleProgesterone receptors in prostate cancer: Progesterone receptor B is the isoform associated with disease progressionen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record